Acura Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged in the research, development and commercialization of products focused on addressing medication abuse and misuse, utilizing its Aversion and Impede Technologies. Aversion is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules designed to address some common methods of product tampering associated with abuse. Impede Technology is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. As of December 31. 2012, the Company had seven additional opioid products utilizing Aversion in various stages of development.
Address
Suite 120, 616 N. North Court
PALATINE, IL 60067-8121
United States
Key stats and ratios
|
| Net profit margin | -105450.00% | - |
| Operating margin | -106100.00% | - |
| EBITD margin | - | - |
| Return on average assets | -62.32% | -29.20% |
| Return on average equity | -66.75% | -30.08% |
| Employees | 15 |
No comments:
Post a Comment